| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_95b960c5f5f7206d4ef3d89ab4550d22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_68bb641731ffa23ead33c51523662490 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H20-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-243
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39541
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 |
| filingDate |
2020-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d080e86ceccda802e5469ebf3255cae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_007f59b03df79ee077b69b6ac6728473
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1332266d448cd57693ae83ca261ed51e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2daa322867f6be5127a12a6d48d1f9dd |
| publicationDate |
2021-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2020231236-A1 |
| titleOfInvention |
Using catequentinib (anlotinib) combining with standard chemotherapy or immunotherapy in sequential order for the cancer treatment |
| abstract |
The present invention relates to a chemo combination therapy regimen to treat cancer. More specifically, the present invention relates to a novel chemo combination therapy regimen which relates to the combination of compound AL3818 (anlotinib, catequentinib) or its pharmaceutically acceptable salts with standard platinum-based and other chemotherapy agents or immunotherapy agents. The combination of these agents should be able to provide higher efficacy than employing any agent individually. |
| priorityDate |
2019-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |